See more : Critical Elements Lithium Corporation (CRECF) Income Statement Analysis – Financial Results
Complete financial analysis of BRIM Biotechnology, Inc. (6885.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BRIM Biotechnology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Shenzhen Huijie Group Co., Ltd. (002763.SZ) Income Statement Analysis – Financial Results
- Xref Limited (XF1.AX) Income Statement Analysis – Financial Results
- ClassWorx, Inc. (CHNO) Income Statement Analysis – Financial Results
- Nordea Invest – Virksomhedsobligationer Højrente (NDIVOHKL1.CO) Income Statement Analysis – Financial Results
- Jet2 plc (JET2.L) Income Statement Analysis – Financial Results
BRIM Biotechnology, Inc. (6885.TWO)
About BRIM Biotechnology, Inc.
BRIM Biotechnology, Inc., a clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases. The company's lead product candidate is BRM 421, a topical ophthalmic solution for patients with moderate-to-severe dry eye syndrome that has completed a phase 2 clinical trial in the United States. It is also developing BRM 423 to treat severe corneal damage, which is in phase 1 clinical trial; BRM 424 for the treatment of neurotrophic keratitis, which is in phase 1 clinical trial; and BRM 521 to relieve and repair tissue damage caused by osteoarthritis. The company was founded in 2013 and is based in Taipei, Taiwan.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 90.00K | 526.00K | 360.00K | 90.77M | 0.00 |
Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 90.00K | 526.00K | 360.00K | 90.77M | 0.00 |
Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
Research & Development | 581.98M | 145.99M | 48.60M | 205.81M | 85.26M |
General & Administrative | 97.50M | 58.73M | 34.57M | 31.32M | 28.05M |
Selling & Marketing | 14.74M | 14.13M | 10.40M | 9.05M | 11.74M |
SG&A | 112.24M | 72.86M | 44.97M | 40.36M | 39.79M |
Other Expenses | 0.00 | 5.92M | 35.32M | 66.79M | 0.00 |
Operating Expenses | 709.76M | 218.85M | 93.58M | 246.17M | 123.89M |
Cost & Expenses | 694.22M | 218.85M | 93.58M | 246.17M | 123.89M |
Interest Income | 21.80M | 829.00K | 500.00K | 1.34M | 0.00 |
Interest Expense | 152.00K | 79.00K | 111.00K | 72.00K | 0.00 |
Depreciation & Amortization | 5.41M | 3.97M | 3.82M | 3.81M | 1.44M |
EBITDA | -682.46M | -270.23M | -93.01M | -83.46M | -116.98M |
EBITDA Ratio | -758,290.00% | -51,374.71% | -28,198.61% | -102.60% | 0.00% |
Operating Income | -694.13M | -274.20M | -105.34M | -96.93M | -125.05M |
Operating Income Ratio | -771,250.00% | -52,128.90% | -29,260.56% | -106.80% | 0.00% |
Total Other Income/Expenses | 6.10M | -55.95M | -12.23M | 58.40M | 3.04M |
Income Before Tax | -688.02M | -274.28M | -105.45M | -97.01M | -122.01M |
Income Before Tax Ratio | -764,468.89% | -52,143.92% | -29,291.39% | -106.88% | 0.00% |
Income Tax Expense | 0.00 | 0.00 | 0.00 | 9.14M | -3.24M |
Net Income | -688.02M | -274.28M | -105.45M | -87.94M | -118.77M |
Net Income Ratio | -764,468.89% | -52,143.92% | -29,291.39% | -96.89% | 0.00% |
EPS | -6.84 | -3.72 | -1.72 | -1.33 | -2.02 |
EPS Diluted | -6.84 | -3.72 | -1.72 | -1.33 | -2.02 |
Weighted Avg Shares Out | 100.55M | 73.74M | 61.33M | 66.03M | 58.78M |
Weighted Avg Shares Out (Dil) | 100.55M | 73.74M | 61.33M | 66.03M | 58.78M |
Source: https://incomestatements.info
Category: Stock Reports